New Delhi: After Thrombosis with Thrombocytopenia Syndrome (TTS), it has now been found that British-Swedish pharma giant AstraZeneca’s COVID-19 vaccine, made in collaboration with Oxford University can raise the risk of Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) , a rare but fatal blood clotting disorder, claimed researchers. While not new, VITT emerged as a new disease following adenovirus vector-based Oxford-AstraZeneca vaccine sold as Covishield in India and Vaxzevria in Europe at the height of the COVID pandemic in 2021, IANS reported.
“An unusually dangerous blood autoantibody directed against a protein termed platelet factor 4 (or PF4)” was found as the reason for VITT.
In separate research in 2023, scientists from Canada, North America, Germany and Italy described a virtually identical disorder with the same PF4 antibody that was fatal in some cases after natural adenovirus (common cold) infection.
Rayagada/Bhubaneswar: Even as paddy procurement is in progress in several districts of Odisha, the unseasonal…
Bhubaneswar: After depression-induced rains for two days, Odisha may witness a gradual fall in the…
Guwahati: A crackdown on illegal child marriages on the night of December 21-22 saw 416…
Bhubaneswar: Prime Minister Narendra Modi held an interaction with a worker from Odisha’s Ganjam during…
Bhubaneswar: Former MLA from Bhubaneswar Central Bijaya Kumar Mohanty breathed his last on Sunday afternoon.…
Mumbai: A four-year-old boy was killed after a speeding car, which was allegedly being driven by…
This website uses cookies.